Get in Touch

Carmine Therapeutics to Present at Biotech Showcase™ 2023

Presenting Tuesday, January 10, 2023 10 AM PST
Franciscan-C, Level Ballroom
Key Takeaways
  • Carmine’s REGENT® gene therapy delivery platform offers several competitive advantages over both AAV and LNP, including safety, tolerability, expression, durability, and applicability.
  • The ability to redose Carmine’s RBCEVs, as well as the flexibility to include multiple payloads beyond the capacity of AAV, while targeting many tropisms, opens the door to the use of gene therapy to  target diseases not previously addressable by first- and second-generation approaches.
  • Carmine is led by industry veterans with decades of experience in the gene and cell therapy market, along with a world renowned scientific advisory and board of directors.

Cambridge, MA/January 5, 2023 – Carmine Therapeutics, today announced that it is presenting at Biotech Showcase™ 2023. This year, registered attendees can view Carmine's presentation live, and also access a recorded version beginning November 29th – SIX weeks prior to the actual event. With 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.

Don Haut, PhD, CEO, will be presenting Carmine Therapeutics at Biotech Showcase.

Date: Tuesday, January 10th, 2023

Time: 10:00am PT

Track: Franciscan C

"Over the past year, we have shown that our platform has enormous potential, delivering DNA payloads of over 30kb, and offering high-amplitude and long-duration transgene expression in a re-dosable and non-inflammatory format. Our first programs in Stargardt disease and Cystic Fibrosis are progressing well towards IND next year. So, I am thrilled to have the opportunity to share Carmine’s data and story at the Biotech Showcase," said Don Haut, PhD, CEO of Carmine Therapeutics.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.

“We are delighted that Carmine Therapeutics will be joining us in San Francisco and presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”


Carmine Therapeutics was founded in 2019 by EVX Ventures, Professor Harvey Lodish (Whitehead, MIT) and Singaporean Professors Minh Le and Jiahai Shi. Professor Lodish, who was a founding member of several successful biotech companies that include Genzyme, Arris (now Axys) Pharmaceuticals, Millennium Pharmaceuticals and Rubius Therapeutics, is also Chair of the Scientific Advisory Board of Carmine. Headquartered in Cambridge, MA with a research presence in Singapore, Carmine is pioneering next generation gene therapy based on red blood cell extracellular vesicles.

About Biotech Showcase
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 15th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

Key Takeaways
  • Carmine’s REGENT® gene therapy delivery platform offers several competitive advantages over both AAV and LNP, including safety, tolerability, expression, durability, and applicability.
  • The ability to redose Carmine’s RBCEVs, as well as the flexibility to include multiple payloads beyond the capacity of AAV, while targeting many tropisms, opens the door to the use of gene therapy to  target diseases not previously addressable by first- and second-generation approaches.
  • Carmine is led by industry veterans with decades of experience in the gene and cell therapy market, along with a world renowned scientific advisory and board of directors.
Media Gallery
Quotes
Over the past year, we have shown that our platform has enormous potential, delivering DNA payloads of over 30kb, and offering high-amplitude and l...
Don Haut, Ph.D.CEO
Related Bios
Don Haut, Ph.D.
CEO
View Full Bio>>
John Robblee, Ph.D
Vice President, CMC
View Full Bio>>
Qin Yu, Ph.D.
Vice President, Discovery
View Full Bio>>
Tenzin Gocha, Ph.D.
Director, Scientific & Business Operations
View Full Bio>>
Ozan Alkan, Ph.D.
Vice President, Molecular Biology
View Full Bio>>
Contacts
Chelli Miller
chelli@contentcarnivores.com
2199216823